20 nov: Indberetning af ledende medarbejders og disses nærtståendes trans..
21 nov: Selskabsmeddelelse 9/2018
20-11-2018 13:20:33

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Relateret indhold
18 jan - 
Fredagens aktier: Flagrende Pandora fløj højest i stige..
18 jan - 
Aktier/middag: Pandora genvinder pusten og topper C25
11 jan - 
Aktier/middag: Danske Bank klarer skærene i afdæmpet ma..
Relateret debat
18 jan - 
Du børge spørge din model om talstørrelser, og om 2018 ..
18 jan - 
I så fald.....bla bla bla....... Undskyld mig, men hvor..
18 jan - 
i så fald skal genmab ned mod 345 området for at lave b..

Company Announcement

Copenhagen, Denmark; November 20, 2018 –

Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 7,588 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

5,000 shares at DKK 174.00,

500 shares at DKK 225.30,

850 shares at DKK 225.90,

500 shares at DKK 234.75,

88 shares at DKK 337.40,

150 shares at DKK 466.20, and

500 shares at DKK 636.50

Proceeds to the company are approximately DKK 1.71 million. The increase corresponds to approx. 0.012 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2018. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No 12 of January 8, 2018, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 61,497,571, which is made up of 61,497,571 shares of a nominal value of DKK 1 each, corresponding to 61,497,571 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 34

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 jan
GEN
Det er flot. Har I overvejet at shorterne sidder og laver tegninger til jer. Genmab vil være eventdr..
6
18 jan
GEN
I så fald.....bla bla bla.......   Undskyld mig, men hvor ser du lige sammenligningen mellem Pandora..
4
15 jan
GEN
Det er vist dig, der er i panik.
4
15 jan
GEN
Mon ikke snart vi får stigninger der vil noget, mon ikke der er et firma der ikke gider at betale ro..
2
15 jan
GEN
Det er modellen fra minutchartet, du har analyseret for signaler, går jeg ud fra ;)   Du skulle nok ..
2
15 jan
GEN
jeg mente 1000-1025 var toppen i december, men den gik lidt mere op grundet januar rally, men det se..
1
14 jan
GEN
Det mere om det ikke blot er panik. Jeg har meget svært ved at tro, når de har fået det godkendt og ..
1

Analytiker: Højere DSV-kurs kan holde konkurrenter fra Panalpina-citat

18-01-2019 13:59:53
Der har været god gænge i DSV-aktien, siden at det onsdag kom frem, at transportgiganten har lagt et bud på den schweiziske konkurrent Panalpina.Kursen er nu 9 pct. højere end før buddet, og det øger chancen for, at DSV løber med selskabet. Sådan lyder det ifølge Jyllands-Posten Finans fra Nordea i en analyse.DSV har nemlig tilbudt både kontantbetaling og DSV-aktier for selskabet - og med den stig..

Jyske Bank mister troen på Pandora

18-01-2019 09:54:35
Jyske Bank ser et mindre potentiale i Pandora efter et svagt julesalg. Banken skærer kursmålet med en fjerdedel, så det nu lyder på 300 kr.Torsdag kom der tal fra den amerikanske smykkekæde Signet Jewels, og heraf fremgik det specifikt, at julesalget af Pandora-smykker fra smykkekoncernens amerikanske forhandlere, Jared, var faldet. Julesalget omfatter både november, december og den første uge af ..

Aktier/tendens: Bavarian kommer med godt nyt i positivt marked

18-01-2019 08:32:42
Godt nyt fra Bavarian Nordic kan fredag give aktien en hovedrolle i et i øvrigt positivt marked, hvor investorerne glæder sig over signaler om en kommende løsning på handelskonflikten mellem USA og Kina.De amerikanske aktier steg ganske pænt torsdag, efter at Wall Street Journal skrev, at USA's finansminister, Steven Mnuchin, på interne strategimøder har foreslået, at USA skal rulle den nyindførte..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Parken-formand: Købstilbud kom ind ad bagdøren
2
Pandora/Citi: Anbefalingen sænkes til "neutral"
3
Nordea: Nordea hjalp kunder med skatteunddragelse - citat
4
Kina: Detailsalg og industriproduktion overrasker en anelse i december
5
Kina: BNP-vækst viste den ventede afmatning i fjerde kvartal

Relaterede aktiekurser

Genmab A/S 1.018,50 -2,9% Fald i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. januar 2019 08:05:04
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB6 - 2019-01-21 08:05:04 - 2019-01-21 08:05:04 - 1 - Website: OKAY